Ulisse BioMed is an innovative StartUp active in healthcare
Founded in 2015, Ulisse BioMed is a global biotech Company with corporate offices in Udine, Italy and Lincolnshire, IL, and with R&D labs in Trieste, Italy and at the IHV (Institute of Human Virology) at the University of Maryland.
Ulisse BioMed is creating novel, innovative and transformative diagnostic platforms and products.
The Company mission and purpose for the science, technologies and products is to create new diagnostic modalities and care models in settings never thought possible throughout the world.

Our History
Timeline
June
Bruna Marini and Rudy Ippodrino create the Easy Pap Team in order to develop cutting-edge technologies for the detection of human pathogens and cancers.
November
The concept of Easy Pap, a small medical device able to detect human Papillomavirus, wins first prize award at the Startup Opportunity Competition in Pordenone (Italy).
Link Article
October
Easy Pap Team is awarded one of the top-5 projects at the Marzotto Award Competition for young entrepreneurs, competing with more than 800 Italian projects; Easy Pap was awarded 30.000€ of incubation and lab services at the Filarete Foundation (Milano, Italy).
Link Article
April
In collaboration with Copernico Sim S.p.a., a joint venture is created. The new Startup is called Ulisse BioMed, in honour of Ulisse, the mithological figure, one of the most famous heroes in the West: curious, smart, brave, Ulisse exploited his intelligence and brilliance to survive and overcome many obstacles.
May
The startup Ulisse BioMed is awarded a major grant, “Smart & Start Invitalia” from the Italian Government, worth 260.000€.
May
Ulisse BioMed successfully completes the first capital increase phase with the support of Copernico Sim.
January
Ulisse BioMed wins 3 European Projects (POR-FESR), in partnership with important national Institutes and Universities
Link Article
February
Ulisse BioMed’s team successfully demonstrates the proof of concept
May
Second round of funding is initiated and completed with 4.995.000 € funding and a total of 1147 shareholders.
September
Ulisse BioMed obtained ISO 9001:2015 certification for Research and Development of new technologies in the medical diagnostic field (IAF-34).
October
Scientific Advisory Board is founded, and includes internationally recognised top scientists: Robert Gallo, Joseph R. Kates, Lawrence Banks, Gordon Whiteley and Davide Zella.
January
Ulisse BioMed opens R&D laboratories at the Institute of Human Virology, University of Maryland, Baltimore (USA)
April
Ulisse BioMed obtained ISO 13485 Certification: it represents the requirements for a comprehensive quality management system for the design and manufacture of medical devices
September
Ulisse BioMed starts the Clinical Trials for his first product: HPV Selfy
July
Ulisse BioMed presents a paper on TDM (Therapeutic Drug Management) at Biosensor Conference in Miami
May
Clinical validation completed